TW202400589A - 四氫異喹啉異雙功能bcl—xl降解劑 - Google Patents

四氫異喹啉異雙功能bcl—xl降解劑 Download PDF

Info

Publication number
TW202400589A
TW202400589A TW112116645A TW112116645A TW202400589A TW 202400589 A TW202400589 A TW 202400589A TW 112116645 A TW112116645 A TW 112116645A TW 112116645 A TW112116645 A TW 112116645A TW 202400589 A TW202400589 A TW 202400589A
Authority
TW
Taiwan
Prior art keywords
group
formula
alkyl
compound
methyl
Prior art date
Application number
TW112116645A
Other languages
English (en)
Chinese (zh)
Inventor
伊凡 J 賀恩
約書華 D 韓森
馬修 D 亞歷山大
黃飛
馬克 A 納吉
Original Assignee
美商樹線生物科學公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商樹線生物科學公司 filed Critical 美商樹線生物科學公司
Publication of TW202400589A publication Critical patent/TW202400589A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW112116645A 2022-05-06 2023-05-04 四氫異喹啉異雙功能bcl—xl降解劑 TW202400589A (zh)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US202263339253P 2022-05-06 2022-05-06
US63/339,253 2022-05-06
US202263398783P 2022-08-17 2022-08-17
US63/398,783 2022-08-17
US202263429862P 2022-12-02 2022-12-02
US63/429,862 2022-12-02
US202363449756P 2023-03-03 2023-03-03
US63/449,756 2023-03-03
US202363454545P 2023-03-24 2023-03-24
US63/454,545 2023-03-24
US202363457997P 2023-04-07 2023-04-07
US63/457,997 2023-04-07

Publications (1)

Publication Number Publication Date
TW202400589A true TW202400589A (zh) 2024-01-01

Family

ID=86688472

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112116645A TW202400589A (zh) 2022-05-06 2023-05-04 四氫異喹啉異雙功能bcl—xl降解劑

Country Status (13)

Country Link
US (1) US20240238423A9 (enExample)
EP (1) EP4519259A1 (enExample)
JP (1) JP2025517642A (enExample)
KR (1) KR20250008772A (enExample)
CN (1) CN119343345A (enExample)
AU (1) AU2023264018A1 (enExample)
CA (1) CA3251489A1 (enExample)
CL (1) CL2024003362A1 (enExample)
IL (1) IL316465A (enExample)
MX (1) MX2024013537A (enExample)
PE (1) PE20250007A1 (enExample)
TW (1) TW202400589A (enExample)
WO (1) WO2023215482A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202527930A (zh) * 2023-11-07 2025-07-16 美商樹線生物科學公司 四氫異喹啉異雙功能bcl-xl降解劑
TW202535872A (zh) * 2023-11-07 2025-09-16 美商樹線生物科學公司 四氫異喹啉異雙功能bcl-xl降解劑
WO2025101575A1 (en) * 2023-11-07 2025-05-15 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-x l degraders
WO2025130875A1 (zh) * 2023-12-18 2025-06-26 南京瑞初医药有限公司 氮杂环化合物及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1888550T3 (pl) 2005-05-12 2014-12-31 Abbvie Bahamas Ltd Promotory apoptozy
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI571466B (zh) * 2011-10-14 2017-02-21 艾伯維有限公司 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑
US8889675B2 (en) 2011-10-14 2014-11-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN109152933B (zh) 2016-04-21 2022-12-02 生物风险投资有限责任公司 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
ES3041854T3 (en) 2018-01-22 2025-11-17 Bioventures Llc Bcl-2 proteins degraders for cancer treatment
CN113660937A (zh) 2019-02-08 2021-11-16 佛罗里达大学研究基金公司 治疗剂和治疗方法
AU2020310147A1 (en) 2019-07-10 2022-01-06 Recurium Ip Holdings, Llc Bcl-2 protein inhibitors
CN112707900B (zh) 2019-10-24 2022-06-10 上海科技大学 蛋白降解剂及其在疾病治疗中的应用
US12441722B2 (en) 2020-01-15 2025-10-14 University Of Florida Research Foundation, Incorporated Therapeutic agents and methods of treatment
US20230167105A1 (en) 2020-04-28 2023-06-01 Recurium Ip Holdings, Llc Bcl-2 protein inhibitors
JP2024505562A (ja) 2021-02-02 2024-02-06 レス ラボラトイレス セルビエル 選択的bcl-xl protac化合物及び使用の方法
US20250197387A1 (en) 2021-09-17 2025-06-19 Kymera Therapeutics, Inc. Bcl-xl degraders and uses thereof
EP4431511A4 (en) * 2021-11-09 2025-10-15 Hangzhou Glubio Pharmaceutical Co Ltd WEE1 PROTEIN KINASE DEGRADING AGENT AND ITS USE

Also Published As

Publication number Publication date
CL2024003362A1 (es) 2025-03-07
EP4519259A1 (en) 2025-03-12
PE20250007A1 (es) 2025-01-07
WO2023215482A1 (en) 2023-11-09
US20240238423A9 (en) 2024-07-18
MX2024013537A (es) 2024-12-06
JP2025517642A (ja) 2025-06-10
AU2023264018A1 (en) 2024-11-07
CA3251489A1 (en) 2023-11-09
US20230390404A1 (en) 2023-12-07
CN119343345A (zh) 2025-01-21
IL316465A (en) 2024-12-01
KR20250008772A (ko) 2025-01-15

Similar Documents

Publication Publication Date Title
JP6348891B2 (ja) Cxcr4受容体アンタゴニスト
JP2025515139A (ja) Kras g12dタンパク質分解標的化キメラ
CN115867554A (zh) Brm靶向化合物和相关使用方法
TW202400589A (zh) 四氫異喹啉異雙功能bcl—xl降解劑
AU2017207268A1 (en) Substituted thiohydantoin derivatives as androgen receptor antagonists
WO2023215471A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
TW202417458A (zh) 調節her2的化合物及方法
WO2022117882A2 (en) Novel par-2 inhibitors
TW202415655A (zh) 1,8—萘啶—2—酮異雙功能bcl6降解劑
WO2023240038A1 (en) Tricyclic quinolone bcl6 bifunctional degraders
AU2023264537A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
CN121752565A (zh) 三环喹诺酮bcl6双官能降解剂
CN120548311A (zh) 分解ikzf2的吲哚化合物及其用途
EP4536649A1 (en) Quinolone bcl6 bifunctional degraders
WO2025101588A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
WO2025101571A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-x l degraders
IL325136A (en) Pyrazolo-pyrimidinone compounds for use in methods for inhibiting kinase week1 a
KR20260062969A (ko) 삼환식 퀴놀론 bcl6 이작용성 분해제
TW202241906A (zh) 吲唑化合物